It’s no secret genetic lab testing is on the rise. Health plan spending in this area is growing at 25-75% per year, and BRCA testing is among the largest categories of genetic testing. However, the market landscape is evolving quickly, and leaders need up-to-date data to make the best decisions about lab contracting, cost management, and payment policies
Drawing on a database of more than 65,000 genetic testing products and experience analyzing the genetic testing claims of more than 100 million members, Concert Genetics brings unique insight to this subject. With this data-rich white paper you’ll have access to:
New data on test pricing trends
Insights into health plan payment experience
Updates on clinical utility and medical policy considerations
To instantly access the report, submit the form on this page.